News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Amol Akhade: The Tyranny of Non-Inferiority Trials
hiranandanihospital.org
Oct 9, 2024, 11:35

Amol Akhade: The Tyranny of Non-Inferiority Trials

Amol Akhade posted the following on LinkedIn:

“The Tyranny of Non-Inferiority Trials.

Excellent view by Professor Ian Tannock in Lancet Oncology.

Should we better call Non-Inferiority Trials as comparative Trials? Bishal Gyawali Bhawna Sirohi.”

The Tyranny of Non-Inferiority Trials

Authors: Prof Ian F Tannock, Marc Buyse, Mickael De Backer, Prof Helena Earl, Prof Daniel A Goldstein, Prof Mark J Ratain, Prof Leonard B Saltz, Prof Gabe S Sonke, Garth W Strohbehn

Amol Akhade: The Tyranny of Non-Inferiority Trials

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital.

He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.

Amol Akhade Bhawna Sirohi Bishal Gyawali Cancer research clinical trials comparative trials Ian Tannock Lancet Oncology non-inferiority trials Oncology
Special Coverage
Blog
Jan 20, 2025, 04:32
Bevacizumab and carboplatin-pemetrexed chemotherapy with/out atezolizumab for advanced pleural mesothelioma
Blog
Jan 20, 2025, 04:29
Katsuaki Maehara: Lung EGFR mutations catalog
Opinion
Jan 20, 2025, 04:25
Elisabetta Bonzano: The identification and validation of patient-specific vulnerabilities
Blog
Jan 20, 2025, 04:21
Robin Zon: Behind every diagnosis, test, approval/ disapproval and outcome is a patient and their family
Insight
Jan 20, 2025, 04:14
Laura Bukavina discusses a paper on BCG treatment for patients with urothelial carcinoma of the prostatic urethra
Insight
Jan 20, 2025, 04:00
FDA approved datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Career
Jan 20, 2025, 03:10
Lawrence “Larry” Deist Appointed to Board of Directors at Rally Foundation for Childhood Cancer Research
Blog
Jan 20, 2025, 02:54
Drew Moghanaki: A new medical oncology position at the VA Medical Center in Long Beach
Science
Jan 20, 2025, 02:44
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical HL
Science
Jan 20, 2025, 02:16
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer
Blog
Jan 20, 2025, 02:14
Akriti Jain: Grateful to present at Cleveland Clinic ASH review
Career
Jan 19, 2025, 23:12
Kimryn Rathmell Steps Down as NCI Director, Concluding a Pivotal Leadership Era